Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 3Myeloproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Hereditary Sensory and Autonomic Neuropathies 2Recurrence 1Primary Myelofibrosis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Fulvestrant 3Alpelisib 3parsaclisib 2Paclitaxel 2Irinotecan 2Cetuximab 2Carboplatin 2tanezumab 1talazoparib 1sotorasib 1serabelisib 1sapanisertib 1ruxolitinib 1olaparib 1niraparib 1liposomal doxorubicin 1inavolisib 1dapagliflozin 1ceralasertib 1binimetinib 1berzosertib 1avelumab 1Vemurafenib 1Topotecan 1Taxes 1SF 1126 1Oxaliplatin 1Lomustine 1Leuprolide 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Hereditary Sensory and Autonomic Neuropathies × parsaclisib × Clear all
NCT03126019 2025-03-14

CITADEL-203

Incyte Corporation

Phase 2 Completed
126 enrolled 15 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Incyte Corporation

Phase 2 Terminated
74 enrolled 40 charts
Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡